Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPE2U: DPYD/DPD Guided Fluoropyrimidine Dosing
NCT04194957Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and fluorouracil in cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of severe fluoropyrimidine-related toxicity. Status: unknown.
02
Drugs
capecitabinefluorouracil
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04194957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194957.